


Active Filter(s):
Details:
IBP-1016 (lactobacillus reuteri) is known to have four interactive mechanisms of action that is gut microbiome and receives FDA orphan drug designation for gastroschisis.
Lead Product(s): Lactobacillus Reuteri
Therapeutic Area: Pediatrics/Neonatology Product Name: IBP-1016
Highest Development Status: Phase I Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 03, 2023